Developer docs
API playgroundTry for free, no card

Search company profiles

Revelation Partners

Full company profile

uuid0000ec2

Namestring
Revelation Partners
Legal namestring
Revelation Capital Management, LLC
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Revelation Partners is a private healthcare-focused secondaries investment manager founded by Scott Halsted following his tenure co-heading healthcare at Morgan Stanley Ventures (1987–2007), where he pioneered the secondary market for healthcare investors. The firm is operated through Revelation Capital Management, LLC (Delaware LLC), headquartered at 300 Turney Street, Sausalito, California, with 11–50 employees and $2.2 billion in committed capital as of May 2026. Its platform delivers three interlocking service lines: Flexible Capital for Healthcare Companies (growth and primary capital into healthcare companies), Shareholder Liquidity Solutions (structured buyouts of founder, employee, angel, and investor stakes in private healthcare companies), and Fund Manager Solutions (LP tenders, GP-led continuation vehicles, portfolio purchases, and fund restructurings for healthcare-focused GPs).

Revenue is generated through management fees on committed capital (the firm closed its third healthcare secondaries fund, Revelation Healthcare Fund III, at a $350 million hard cap in February 2025) and carried interest on realizations. In October 2024, Kudu Investment Management took a minority strategic stake to support growth and distribution. Notable portfolio transactions include leading VitalConnect's $30M Series F, participating in Metabolon's $25M primary financing, acquiring common shares from early employees of Iris Telehealth, purchasing a 15-asset healthcare portfolio from GE Ventures, and co-financing Bluejay Capital's recapitalization of Quality Life Science Logistics & Transportation.

The senior team is concentrated in healthcare-domain expertise: Managing Partners Scott Halsted and Mike Boggs, Partner/CFO Prashant Gangwal (joined 2026 from Altos Ventures), Partners Doug Fisher (biopharma/diagnostics/medical devices), Fred Lee, Eric Shiozaki (biopharma/medical devices, promoted November 2025), Jonathan Au (secondaries, joined 2026 from CVC Secondary Partners), plus Principals, Senior Associates, and Associates sourced from Goldman Sachs, Wells Fargo Strategic Capital, SoftBank, Carlyle AlpInvest, and Bluejay BioAdvisors. The firm operates a single integrated investment platform rather than a modular product suite, and there is no evidence of proprietary technology or AI/ML systems — competitive differentiation is sourced from sector specialization, deal structuring capabilities, and GP/founder relationships.

Short descriptiontext

Revelation Partners is a private healthcare-focused secondaries investment manager, providing flexible capital, shareholder liquidity, and fund manager solutions to private healthcare companies and GPs, with $2.2 billion in committed capital and a $350M Fund III closed in February 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSausalito, United States
HQ citystring
Sausalito
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
healthcare secondaries investing, private equity funds, healthcare investment management, shareholder liquidity solutions, fund manager solutions
Industry3 codes
PRIMARYFSANAFAL
Emerging Manager / Small Fund Secondaries
Financial & Insurance/Private Equity & Venture Capital/Secondaries Funds (LP Stakes & GP-led)
SECONDARYFSAHALAK
GP-led Secondaries — Fund Restructurings / Tender Offers / Recaps
Financial & Insurance/Hedge Funds & Alternative Investments/Alternative Investments — Secondaries (LP Stakes, GP-led)
SECONDARYFSAEALAG
Secondaries Fundraising & Liquidity Intermediation (LP Stakes/GP-led)
Financial & Insurance/Financial Advisory, Brokerage & Intermediation/Placement Agents & Capital Raising Intermediation
NAICS code1 code
  • Trusts, Estates, and Agency Accounts52592
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Secondaries Investment Management
Social media profiles1 record
Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Revelation Partners is a private healthcare-focused secondaries investment manager that provides flexible capital to growth-stage healthcare companies, designs customized shareholder liquidity programs (for founders, early employees, and early investors), and partners with healthcare-focused venture and growth fund managers to deliver GP-led liquidity solutions including continuation vehicles, LP tenders, and fund restructurings. Its offerings are funded through its dedicated healthcare secondaries funds, with Revelation Healthcare Fund III closed at a $350 million hard cap in February 2025.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Revelation Partners operates a single integrated investment platform focused on healthcare secondaries, delivered through three interlocking service lines: Flexible Capital for Healthcare Companies, Shareholder Liquidity Solutions, and Fund Manager Solutions. These offerings are funded and scaled through the firm's flagship vehicles, including Revelation Healthcare Fund III ($350M hard cap, February 2025), and complement one another — Flexible Capital for Healthcare Companies anchors the deal origination pipeline, Shareholder Liquidity Solutions provides structured exits for company stakeholders, and Fund Manager Solutions supports healthcare-focused GPs. Together, they form a unified secondaries platform rather than a modular product suite.

Product and service4 records
1Flexible Capital for Healthcare Companies
CategoryInvestment service — direct & secondary capital to healthcare companies
Description

Flexible, tailored secondary-market capital provided to growth-stage privately held healthcare companies, enabling them to fund growth, extend runway, or provide shareholder liquidity without a traditional primary financing round. The firm invests in rapidly growing healthcare companies and actively partners with management teams to scale, while also creating customized solutions that provide liquidity and align shareholders. Includes growth capital and shareholder liquidity solutions (founder, early employee, venture/PE fund, corporate investor, and angel investor liquidity).

2Shareholder Liquidity Solutions
CategoryInvestment service — shareholder secondaries
Description

Customized secondary transactions that provide liquidity to the shareholders of privately held healthcare companies, including founders, early employees, venture and private equity funds, corporate investors, and angel investors, while balancing shareholder needs with company-stage considerations.

3Fund Manager Solutions
CategoryInvestment service — GP-led secondaries and fund restructurings
Description

Partnership solutions for healthcare-focused venture and growth fund managers and their LPs, including direct share purchases, follow-on capital, multi- and single-asset transactions, continuation funds, fund restructurings, and LP tenders. The firm partners with the GP to provide liquidity solutions to limited partners and tailors specialized solutions for a wide range of counterparties.

4Revelation Healthcare Fund III
CategoryFlagship investment vehicle (fund)
Description

The firm's third healthcare-focused secondaries fund, closed at a $350 million hard cap in February 2025. The fund provides the capital that backs the firm's Flexible Capital for Healthcare Companies, Shareholder Liquidity Solutions, and Fund Manager Solutions offerings.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare-focused secondary investment manager providing liquidity solutions to venture and growth-stage healthcare companies and their investors. Direct competitor to Revelation's Flexible Capital and Shareholder Liquidity service lines, with overlapping target markets and LP base.

TypeDirect peer
Description

Multi-strategy secondaries investment manager now part of CVC Capital Partners, with significant healthcare exposure across LP stakes and GP-led transactions. Directly comparable on transaction structure and healthcare focus; competitor for both portfolio secondaries and GP-led continuation vehicles.

TypeBroad incumbent
Description

One of the largest and most established secondary investment managers globally, with broad sector exposure including dedicated healthcare secondaries activity. Larger, more diversified incumbent competing for both LP-stake and GP-led healthcare opportunities.

4Ardian
TypeBroad incumbent
Description

Global private investment house with a leading Secondary Fund of Funds franchise and growing direct/GPS platform. Active in healthcare secondaries; broader incumbent offering scale advantages and access to LPs and GPs worldwide.

TypeDirect peer
Description

Specialist secondaries and fund-of-funds manager focused on venture capital, with significant healthcare VC exposure. Comparable model of LP-stake purchases, GP-led solutions, and direct secondaries in growth-stage companies.

TypeBroad incumbent
Description

Large global private markets investment manager with active secondary funds-of-funds and partnership solutions programs, including healthcare exposure. Broader incumbent offering scale, multi-strategy mandates, and global LP distribution.

TypeBroad incumbent
Description

Global private markets investment firm with a dedicated secondaries platform covering LP secondaries and GP-led transactions. Larger, more diversified competitor with growing healthcare coverage.

TypeEmerging player
Description

Healthcare-focused investment firm operating across venture, growth, and public equities with a meaningful US and Asia presence. Comparable healthcare-only thesis but with primary investment orientation rather than dedicated secondaries platform.

TypeBroad incumbent
Description

Major GP-led secondaries platform within Blackstone, executing large continuation vehicles and GP-stake transactions. Increasingly relevant competitor on the GP-led side of Revelation's Fund Manager Solutions offering.

TypeBroad incumbent
Description

Large global private markets investment manager with established secondary fund-of-funds and primaries platforms, including healthcare exposure. Broader incumbent with global LP distribution capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment57 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Revelation Partners

Healthcare Secondaries Investment Managementrevelation-partners.com

Revelation Partners is a private healthcare-focused secondaries investment manager, providing flexible capital, shareholder liquidity, and fund manager solutions to private healthcare companies and GPs, with $2.2 billion in committed capital and a $350M Fund III closed in February 2025.

What Revelation Partners does

Revelation Partners is a private healthcare-focused secondaries investment manager founded by Scott Halsted following his tenure co-heading healthcare at Morgan Stanley Ventures (1987–2007), where he pioneered the secondary market for healthcare investors. The firm is operated through Revelation Capital Management, LLC (Delaware LLC), headquartered at 300 Turney Street, Sausalito, California, with 11–50 employees and $2.2 billion in committed capital as of May 2026. Its platform delivers three interlocking service lines: Flexible Capital for Healthcare Companies (growth and primary capital into healthcare companies), Shareholder Liquidity Solutions (structured buyouts of founder, employee, angel, and investor stakes in private healthcare companies), and Fund Manager Solutions (LP tenders, GP-led continuation vehicles, portfolio purchases, and fund restructurings for healthcare-focused GPs).

Revenue is generated through management fees on committed capital (the firm closed its third healthcare secondaries fund, Revelation Healthcare Fund III, at a $350 million hard cap in February 2025) and carried interest on realizations. In October 2024, Kudu Investment Management took a minority strategic stake to support growth and distribution. Notable portfolio transactions include leading VitalConnect's $30M Series F, participating in Metabolon's $25M primary financing, acquiring common shares from early employees of Iris Telehealth, purchasing a 15-asset healthcare portfolio from GE Ventures, and co-financing Bluejay Capital's recapitalization of Quality Life Science Logistics & Transportation.

The senior team is concentrated in healthcare-domain expertise: Managing Partners Scott Halsted and Mike Boggs, Partner/CFO Prashant Gangwal (joined 2026 from Altos Ventures), Partners Doug Fisher (biopharma/diagnostics/medical devices), Fred Lee, Eric Shiozaki (biopharma/medical devices, promoted November 2025), Jonathan Au (secondaries, joined 2026 from CVC Secondary Partners), plus Principals, Senior Associates, and Associates sourced from Goldman Sachs, Wells Fargo Strategic Capital, SoftBank, Carlyle AlpInvest, and Bluejay BioAdvisors. The firm operates a single integrated investment platform rather than a modular product suite, and there is no evidence of proprietary technology or AI/ML systems — competitive differentiation is sourced from sector specialization, deal structuring capabilities, and GP/founder relationships.

Revelation Partners firmographics

Firmographics
Name
Revelation Partners
Legal name
Revelation Capital Management, LLC
Website
https://revelation-partners.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Revelation Partners is a private healthcare-focused secondaries investment manager, providing flexible capital, shareholder liquidity, and fund manager solutions to private healthcare companies and GPs, with $2.2 billion in committed capital and a $350M Fund III closed in February 2025.
Ownership category
akta.pro rank

Revelation Partners industry classification

Industry
Product category
Healthcare Secondaries Investment Management
NAICS
Trusts, Estates, and Agency Accounts (52592)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAFAL
Emerging Manager / Small Fund Secondaries
Financial & Insurance/Private Equity & Venture Capital/Secondaries Funds (LP Stakes & GP-led)
SECONDARYFSAHALAK
GP-led Secondaries — Fund Restructurings / Tender Offers / Recaps
Financial & Insurance/Hedge Funds & Alternative Investments/Alternative Investments — Secondaries (LP Stakes, GP-led)
SECONDARYFSAEALAG
Secondaries Fundraising & Liquidity Intermediation (LP Stakes/GP-led)
Financial & Insurance/Financial Advisory, Brokerage & Intermediation/Placement Agents & Capital Raising Intermediation

Keywords

  • Healthcare secondaries investing
  • Private equity funds
  • Healthcare investment management
  • Shareholder liquidity solutions
  • Fund manager solutions

Where Revelation Partners is headquartered

Location

Headquarters

HQ city
Sausalito
HQ country
United States
HQ region
North America

Markets served

Revelation Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revelation Partners product offering

Product offering

Core offering

Revelation Partners is a private healthcare-focused secondaries investment manager that provides flexible capital to growth-stage healthcare companies, designs customized shareholder liquidity programs (for founders, early employees, and early investors), and partners with healthcare-focused venture and growth fund managers to deliver GP-led liquidity solutions including continuation vehicles, LP tenders, and fund restructurings. Its offerings are funded through its dedicated healthcare secondaries funds, with Revelation Healthcare Fund III closed at a $350 million hard cap in February 2025.

Product overview

Revelation Partners operates a single integrated investment platform focused on healthcare secondaries, delivered through three interlocking service lines: Flexible Capital for Healthcare Companies, Shareholder Liquidity Solutions, and Fund Manager Solutions. These offerings are funded and scaled through the firm's flagship vehicles, including Revelation Healthcare Fund III ($350M hard cap, February 2025), and complement one another — Flexible Capital for Healthcare Companies anchors the deal origination pipeline, Shareholder Liquidity Solutions provides structured exits for company stakeholders, and Fund Manager Solutions supports healthcare-focused GPs. Together, they form a unified secondaries platform rather than a modular product suite.

Differentiator

Problem solved

Functional benefit

Products and services

  • Flexible Capital for Healthcare Companies Flexible, tailored secondary-market capital provided to growth-stage privately held healthcare companies, enabling them to fund growth, extend runway, or provide shareholder liquidity without a traditional primary financing round. The firm invests in rapidly growing healthcare companies and actively partners with management teams to scale, while also creating customized solutions that provide liquidity and align shareholders. Includes growth capital and shareholder liquidity solutions (founder, early employee, venture/PE fund, corporate investor, and angel investor liquidity).
  • Shareholder Liquidity Solutions Customized secondary transactions that provide liquidity to the shareholders of privately held healthcare companies, including founders, early employees, venture and private equity funds, corporate investors, and angel investors, while balancing shareholder needs with company-stage considerations.
  • Fund Manager Solutions Partnership solutions for healthcare-focused venture and growth fund managers and their LPs, including direct share purchases, follow-on capital, multi- and single-asset transactions, continuation funds, fund restructurings, and LP tenders. The firm partners with the GP to provide liquidity solutions to limited partners and tailors specialized solutions for a wide range of counterparties.
  • Revelation Healthcare Fund III The firm's third healthcare-focused secondaries fund, closed at a $350 million hard cap in February 2025. The fund provides the capital that backs the firm's Flexible Capital for Healthcare Companies, Shareholder Liquidity Solutions, and Fund Manager Solutions offerings.

Companies that use Revelation Partners

Customer profile

Ideal customer profiles4 records

Revelation Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Revelation Partners partnerships and signals

Strategic signal

Recent moves7 records

Expansion highlights5 records

Revelation Partners competitors and assessment

Company assessment

Direct peers

  • NewView Capital: Healthcare-focused secondary investment manager providing liquidity solutions to venture and growth-stage healthcare companies and their investors. Direct competitor to Revelation's Flexible Capital and Shareholder Liquidity service lines, with overlapping target markets and LP base.
  • Glendower Capital (CVC Secondary Partners): Multi-strategy secondaries investment manager now part of CVC Capital Partners, with significant healthcare exposure across LP stakes and GP-led transactions. Directly comparable on transaction structure and healthcare focus; competitor for both portfolio secondaries and GP-led continuation vehicles.
  • Industry Ventures: Specialist secondaries and fund-of-funds manager focused on venture capital, with significant healthcare VC exposure. Comparable model of LP-stake purchases, GP-led solutions, and direct secondaries in growth-stage companies.

Broad incumbents

  • Lexington Partners: One of the largest and most established secondary investment managers globally, with broad sector exposure including dedicated healthcare secondaries activity. Larger, more diversified incumbent competing for both LP-stake and GP-led healthcare opportunities.
  • Ardian: Global private investment house with a leading Secondary Fund of Funds franchise and growing direct/GPS platform. Active in healthcare secondaries; broader incumbent offering scale advantages and access to LPs and GPs worldwide.
  • HarbourVest Partners: Large global private markets investment manager with active secondary funds-of-funds and partnership solutions programs, including healthcare exposure. Broader incumbent offering scale, multi-strategy mandates, and global LP distribution.
  • StepStone Group: Global private markets investment firm with a dedicated secondaries platform covering LP secondaries and GP-led transactions. Larger, more diversified competitor with growing healthcare coverage.
  • Blackstone GP Stakes: Major GP-led secondaries platform within Blackstone, executing large continuation vehicles and GP-stake transactions. Increasingly relevant competitor on the GP-led side of Revelation's Fund Manager Solutions offering.
  • LGT Capital Partners: Large global private markets investment manager with established secondary fund-of-funds and primaries platforms, including healthcare exposure. Broader incumbent with global LP distribution capabilities.

Emerging players

  • Vivo Capital: Healthcare-focused investment firm operating across venture, growth, and public equities with a meaningful US and Asia presence. Comparable healthcare-only thesis but with primary investment orientation rather than dedicated secondaries platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revelation Partners social profiles

Digital presence

Revelation Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Revelation Partners leadership team

Management profile

Number of profiles

Profiles12 records

Revelation Partners funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Revelation Partners M&A and investment

M&A and investment

M&A

Investments57 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revelation Partners

What does Revelation Partners do?

Revelation Partners is a private healthcare-focused secondaries investment manager that provides flexible capital to growth-stage healthcare companies, designs customized shareholder liquidity programs (for founders, early employees, and early investors), and partners with healthcare-focused venture and growth fund managers to deliver GP-led liquidity solutions including continuation vehicles, LP tenders, and fund restructurings. Its offerings are funded through its dedicated healthcare secondaries funds, with Revelation Healthcare Fund III closed at a $350 million hard cap in February 2025.

Is Revelation Partners a public or private company?

Revelation Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Revelation Partners founded?

Revelation Partners was founded in 2012. It employs 11 to 50 people.

Where is Revelation Partners based?

Revelation Partners is headquartered in Sausalito, United States, in the North America region.

Who are Revelation Partners's main competitors?

Direct peers on record are NewView Capital, Glendower Capital (CVC Secondary Partners) and Industry Ventures. Broad incumbents are Lexington Partners, Ardian, HarbourVest Partners, StepStone Group, Blackstone GP Stakes and LGT Capital Partners. Vivo Capital is listed as an emerging player.

Does Revelation Partners have an API?

No public API is recorded for Revelation Partners.

What industry is Revelation Partners in?

Revelation Partners's product category is Healthcare Secondaries Investment Management. Its primary akta.pro industry code is FSANAFAL, Emerging Manager / Small Fund Secondaries, with a secondary code of FSAHALAK, GP-led Secondaries — Fund Restructurings / Tender Offers / Recaps. Its NAICS code is 52592 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooNouscom Raises €120 Million ($135 Million) in Oversubscribed Series D Financing and will Present Long-Term Cancer Interception Clinical Data in Lynch Syndrome Carriers at ESMONouscom closed an oversubscribed €120 million Series D financing led by M Ventures and Revelation Partners. Proceeds will fund a global registration-enabling trial of its NOUS-209 neoantigen vaccine in Lynch Syndrome carriers, with long-term cancer interception data to be presented at ESMO.LinkedInRevelation PartnersRevelation Partners announced a partnership with Nordic Capital to enter a new growth phase. The strategic investment strengthens its ability to scale and deliver data-driven intelligence for healthcare sustainability. The company looks forward to accelerating expansion with Nordic Capital as its new majority owner.Pulse 2.0Revelation Partners Appoints Prashant Gangwal As Partner And Chief Financial OfficerRevelation Partners appointed Prashant Gangwal as partner and chief financial officer. He previously served as CFO at Altos Ventures and held finance roles at NewView Capital and SharesPost. The firm manages $2.2 billion in committed capital and focuses on private healthcare secondaries.HrtodayHealthcare Secondaries Manager Revelation Partners Appoints Prashant Gangwal as Partner and CFORevelation Partners, the largest secondaries investment manager focused solely on private healthcare, has appointed Prashant Gangwal as partner and chief financial officer. Gangwal brings extensive experience in venture capital, private equity, and secondary transactions from previous CFO roles at Altos Ventures, NewView Capital, and SharesPost. The appointment supports Revelation Partners' continued growth as a healthcare-focused investment manager with $2.2 billion of committed capital.PR NewswireHealthcare Secondaries Manager Revelation Partners Appoints Prashant Gangwal as Partner and CFORevelation Partners, the largest secondaries investment manager focused solely on private healthcare, has appointed Prashant Gangwal as Partner and Chief Financial Officer. Gangwal joins from Altos Ventures and previously held CFO and founding team roles at NewView Capital, as well as leadership positions at SharesPost and early career experience at Deloitte. The appointment is part of Revelation Partners' continued buildout as the premier healthcare secondaries manager, which currently manages $2.2 billion in committed capital.PR NewswireRevelation Partners Deepens Secondaries Expertise with Appointment of Jonathan Au as Partner and Jordan Bloom as AssociateRevelation Partners, a secondaries investment manager focused on private healthcare, announced the appointment of Jonathan Au as Partner and Jordan Bloom as Associate to strengthen its secondary transactions and GP-led transaction capabilities. Au joins from CVC Secondary Partners where he managed relationships with over 25 U.S. buyout firms, while Bloom comes from Carlyle Group's AlpInvest Secondaries team, a $20 billion platform. The firm, headquartered in Sausalito with $1.5 billion in committed capital, stated these hires reinforce its expertise in delivering creative capital solutions to private healthcare stakeholders.Revelation PartnersGSK spins out corporate VC fund focused on bioelectronic tech – Revelation PartnersGSK has spun out its corporate venture unit, Action Potential Venture Capital (APVC), into a new independent entity called the Synapse Fund. The new fund is backed by SR One, healthcare investor Revelation Partners, and other undisclosed limited partners.InforcapitalRevelation PartnersRevelation Partners is a healthcare-focused investment firm that provides flexible capital and liquidity solutions to privately-held healthcare companies. Headquartered in Sausalito, California, the firm manages over $1.5 billion in assets and invests primarily in late-stage private companies with validated technologies or commercial scale.PR NewswireAspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy ProgramsAspen Neuroscience announced the closing of an $115 million Series C financing round to accelerate clinical development and commercial readiness for its lead Parkinson's disease therapy, ANPD001. The investment was co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and Revelation Partners, with participation from new investor Kite, a Gilead Company. Aspen also appointed Cindy Perettie, Global Head of Kite, to its board of directors as part of this strategic expansion.ThemiddlemarketRevelation Partners Names Eric Shiozaki PartnerRevelation Partners has appointed Eric Shiozaki as a partner to advance its leadership team and deepen sector expertise in biotechnology and medical devices. This move comes amid record dealflow in the healthcare secondaries market, leveraging Shiozaki's 25+ years of experience from previous roles at firms like DCVC Bio and Novo Holdings.